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Abstract
The treatment of metastatic melanoma has changed dramatically in the last decade with the introduction of
immunotherapy and targeted therapy. A futile disease in the past is now treated with various options,
resulting in improvement in progression-free and overall survivals, along with improvement in the quality
of life. Having said that, the majority of patients with metastatic melanoma eventually succumb to the
disease. Molecular profiling of each tumor in the advanced stage is standard of care now, as this would lead
to individualized treatment options for each patient. Here, we present a rare case of fibroblast growth factor
receptor 3 (FGFR 3) amplified metastatic melanoma, treated rather unconventionally with FGFR 3 inhibitor
erdafitinib.
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Introduction
Over the past two decades, the incidence of cutaneous melanoma has increased substantially, according to
the Surveillance, Epidemiology and End Results database, from 38,000 in 1997 to 76,000 in 2016 [1]. Prior to
the introduction of immunotherapy and targeted therapy, metastatic melanoma was historically treated
with chemotherapeutic agents, such as dacarbazine and its prodrug temozolomide. Platinum agents were
also used, albeit less frequently. The outcomes during the era of chemotherapy in metastatic melanomas
were poor and prognosis dismal.
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Tumor profiling led to substantial improvement in our understanding of the pathophysiology of advanced
melanomas. In 40%-60% of advanced melanomas, activating mutations are identified in BRAF V600E [2-4].
This led to clinical trials directly inhibiting BRAF, along with other trials looking at combination BRAF/MEK
inhibition, leading to significant improvement in overall survival. Fibroblast growth factor receptor 3 (FGFR
3) is mutated in approximately 3.2% of patients with melanoma [5]. In a study by Li et al., FGFR3 alteration
was highly expressed in cutaneous metastatic melanomas, and associated with increased Breslow thickness
and lymph node metastases [6]. It is also noted that FGFR3 alteration is seen more in metastatic melanoma
cells than the primary tumor [7]. Overexpression of FGFR3 has also been associated with several types of
cancer, including multiple myeloma, bladder cancer, non-small cell lung cancer oropharyngeal squamous
cell carcinoma [8-11].

Case Presentation
A 29-year-old woman presented to our hospital with shortness of breath and back pain. CT scan revealed a
large right-sided pleural effusion, right paraspinal 7 cm soft tissue mass, and pericardial and right
tracheobronchial lymphadenopathy. She underwent thoracentesis at which time 2.5L bloody fluid was
removed. Cytology was positive for malignancy. CT-guided biopsy of the soft tissue mass revealed
melanoma. Positron emission tomography/computed tomography (PET/CT) revealed hypermetabolic lesions
in the right pleura, extensive mediastinal lymphadenopathy, adrenal and peritoneal metastases with occult
primary on dermatology exam. MRI of the brain was negative.
Tumor profiling revealed BRAF, KIT, NTRK1/2/3, N/K/HRAS wild type disease. Pathology was confirmed at
Brigham and Women’s and Memorial Sloan Kettering. She was started on combination immunotherapy with
ipilimumab 3mg/kg and nivolumab 1 mg/kg every 21 days. Her course was complicated by post-treatment
pleuritic pain which required brief interruption of combination anti-CTLA4 and PD1 inhibitors and short
course of prednisone.
After four cycles of treatment, restaging PET/CT revealed worsening mediastinal and retroperitoneal
adenopathy (Figure 1). MRI of the brain revealed 20 mostly sub-centimeter lesions suggesting
metastases. She was given palliative carboplatin/paclitaxel and had gamma knife to 10 of the largest brain
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lesions. She only received one cycle of carboplatin/paclitaxel and had clinical progression with increased
cervical lymphadenopathy and increased daily bloody pleural drainage, around 400cc per day. STRATA
Oncology NexGenSequencing revealed FGFR3 amplification with an estimated copy number of nine.

FIGURE 1: PET/CT prior to initiation of erdafitinib
PET/CT, positron emission tomography/computed tomography

We obtained approval to use erdafitinib on a compassionate use program. This drug is approved for the
treatment of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic
alterations, that has progressed during or following platinum-containing chemotherapy, including within 12
months of neoadjuvant or adjuvant platinum-containing chemotherapy [12]. She tolerated erdafitinib 8
mg/day well and within three days, her drainage requirements decreased dramatically and her symptoms
resolved. Restaging PET/CT was performed at 12 weeks showing a 95% resolution of systemic disease and

2020 Sarkisian et al. Cureus 12(10): e11231. DOI 10.7759/cureus.11231

2 of 4

metabolic uptake (Figure 2). MRI of the brain at six weeks showed overall stability of the brain lesions and
dexamethasone was able to be weaned. At 16 weeks, extracranial disease was controlled, however, the
patient developed seizures and progression in the brain. MRI brain then showed 40 metastatic lesions and
leptomeningeal changes. She received whole-brain radiation therapy. Her overall course was complicated by
worsening brain metastases and declining performance status. Repeat MRI brain revealed even more brain
metastases resulting is significant morbidity, eventually the patient was transitioned to hospice care and
passed away.

FIGURE 2: PET/CT after erdafitinib
PET/CT, positron emission tomography/computed tomography

Discussion
Erdafitinib is a pan fibroblast growth factor receptor kinase inhibitor that was approved in locally advanced
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or metastatic urothelial carcinoma based on BCL2001 trial. This was an open label, phase 2 study that
included a total of 99 patients with disease progression during or after at least one course of chemotherapy
or within 12 months after neoadjuvant or adjuvant chemotherapy [13]. For this specific patient population,
Erdafitinib led to median progression-free survival and overall survival of 5.5 months and 13.8 months,
respectively. FGFR alteration is rare in melanoma. To our knowledge, this is the first case of FGFR 3-altered
metastatic melanoma that was treated with Erdafitinib with significant response, albeit brief, after
refractoriness to immunotherapy and chemotherapy. The discordant response in the brain and the rest of
her body suggests either poor central nervous system (CNS) penetration of erdafitinib or more resistant
mutations in the brain metastases. Our patient derived dramatic response and benefit with stabilization of
extracranial disease from erdafitinib that lasted for approximately 27 weeks prior to progression. Clinical
trials of FGFR 3 inhibitors in advanced melanoma driven by FGFR 3 alterations are warranted and better
strategies for CNS disease control is needed. Through this personalized approach, we were able to prolong
our patient's survival with improving her quality of life as well, however this short and substantial benefit
would lead us to believe that further mutations or alterations have happened which we have not identified
yet leading to this discordant response.

Conclusions
Immunotherapy and targeted therapy have improved the survival of patients with advanced melanomas.
This case highlights that FGFR amplifications are a potentially relevant receptor tyrosine kinase in
melanoma in general, and that FGFR2/3 inhibition could represent an additional target beyond
BRAF/KIT/RAS/NTRK that could spur basket clinical trial participation. Through this case, we shed light on
this rare clinical scenario with the hope of increasing awareness in helping other patients and the
importance of personalized approach in caring for oncology patients in general.
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